SMART-C Meta-Analysis: SGLT2 Inhibitors Reduce Cardiovascular Events

Meta-analysis of 11 phase 3 trials shows SGLT2 inhibitors reduce cardiovascular event risk by 9% across diverse patient populations.

Related Keywords

,George Institute For Global Health ,Renal Trialist Consortium ,Brendon Neuen ,Research Fellow ,George Institute ,Analysis Cardio Renal Trialist Consortium ,Hazard Ratio ,Confidence Interval ,Glucose Co Transporter ,Major Adverse Cardiovascular Outcomes ,Redefining Cardiometabolic ,